Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amantadine
Drug ID BADD_D00097
Description An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.
Indications and Usage For the chemoprophylaxis, prophylaxis, and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Also for the treatment of parkinsonism and drug-induced extrapyramidal reactions.
Marketing Status approved
ATC Code N04BB01
DrugBank ID DB00915
KEGG ID D07441
MeSH ID D000547
PubChem ID 2130
TTD Drug ID D02KRS
NDC Product Code 11014-0245; 70482-075; 46708-246; 62332-246; 70482-076; 62332-586; 70482-170; 60687-422; 70482-085; 11014-0234; 46708-586
UNII BF4C9Z1J53
Synonyms Amantadine | 1-Aminoadamantane | 1 Aminoadamantane | Adamantylamine | Wiregyt | Amanta | Amanta-HCI-AZU | Amanta HCI AZU | AmantaHCIAZU | Amanta-Sulfate-AZU | Amanta Sulfate AZU | AmantaSulfateAZU | Amantadin AZU | AZU, Amantadin | Amantadin AL | AL, Amantadin | Amantadin Stada | Stada, Amantadin | Amantadin-neuraxpharm | Amantadin neuraxpharm | Amantadinneuraxpharm | Amantadin-ratiopharm | Amantadin ratiopharm | Amantadinratiopharm | Amantadina Juventus | Juventus, Amantadina | Amantadina Llorente | Llorente, Amantadina | Amantadine Hydrochloride | Hydrochloride, Amantadine | Amantadine Sulfate | Sulfate, Amantadine | Amixx | Cerebramed | Gen-Amantadine | Gen Amantadine | GenAmantadine | Infecto-Flu | Infecto Flu | InfectoFlu | Infex | Midantan | PMS-Amantadine | PMS Amantadine | PMSAmantadine | Symadine | Symmetrel | Endantadine | Mantadix | tregor | Viregyt | Adekin | Aman
Chemical Information
Molecular Formula C10H17N
CAS Registry Number 768-94-5
SMILES C1C2CC3CC1CC(C2)(C3)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abnormal dreams19.02.03.001; 17.15.02.0010.002201%Not Available
Acute psychosis19.03.01.0010.000983%Not Available
Acute respiratory failure22.02.06.001; 14.01.04.004--Not Available
Aggression19.05.01.001--Not Available
Agitation19.06.02.001; 17.02.05.0120.001179%
Agranulocytosis01.02.03.001--Not Available
Alopecia23.02.02.001--
Amnesia19.20.01.001; 17.03.02.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anxiety19.06.02.002--
Arrhythmia02.03.02.001--Not Available
Asthenia08.01.01.001--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Blindness unilateral06.02.10.007; 17.17.01.0160.000590%Not Available
Body temperature decreased13.15.01.010--Not Available
Body temperature increased13.15.01.001--Not Available
Cardiac arrest02.03.04.0010.000983%
Cardiac failure02.05.01.001--
Cardiac failure congestive02.05.01.002--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.0070.000590%
Choking22.12.03.0030.000865%Not Available
Chorea17.01.01.0010.000393%Not Available
Coma17.02.09.001--Not Available
Completed suicide19.12.01.001; 08.04.01.0100.000393%Not Available
Condition aggravated08.01.03.0040.001730%Not Available
Confusional state19.13.01.001; 17.02.03.0050.002791%
Constipation07.02.02.0010.003066%
Corneal oedema06.04.02.0010.001061%Not Available
Corneal opacity06.06.03.005--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages